THNR 股價展望與 ETF 分析 - 配息·管理費·持股·NAV·RSI·MACD

THNR

Amplify Weight Loss Drug & Treatment ETF

收盤價 10月30日 11:41 AM ET（韓國 10/31 24:41）

$25.95

+0.59 ▲ +2.33%

擴散形態阻力線 28.21 支撐線 23.49 維持由 AI 繪製的參考線，可能有誤，僅供參考，並非預測。

詳細指標表

Category ⓘ	Global or ExUS Equities - Industry Sector	Expense ⓘ	0.59%	Return% 1Y ⓘ	11.16%	Total Holdings ⓘ	22	Perf Week ⓘ	5.04%	Volume ⓘ	1,107
Asset Type ⓘ	Equities (Stocks)	AUM ⓘ	$6M	Return% 3Y ⓘ	-	NAV ⓘ	$25.33	Perf Month ⓘ	5.07%	Avg Volume ⓘ	0.00M
ETF Type ⓘ	Global Equities	Dividend TTM ⓘ	$0.41 (1.59%)	Return% 5Y ⓘ	-	52W High ⓘ	-7.14%	Perf Quarter ⓘ	2.58%	Rel Volume ⓘ	0.88
Active/Passive ⓘ	Passive	Div Gr. 3/5Y ⓘ	-	Return% 10Y ⓘ	-	52W Low ⓘ	13.35%	Perf Half Y ⓘ	5.36%	Prev Close ⓘ	$25.36
IPO ⓘ	2024/5/21	Flows% 1M ⓘ	0%	Return% SI ⓘ	0.98%	RSI (14) ⓘ	63.21	Perf YTD ⓘ	2.88%	Price ⓘ	$25.95
Beta ⓘ	0.43	Flows% 3M ⓘ	14.94%	Flows% YTD ⓘ	111.87%	Flows% 1Y ⓘ	111.87%	Perf Year ⓘ	13.05%	Volatility(W/M) ⓘ	0.87% 1.11%
SMA20 ⓘ	5.12%	SMA50 ⓘ	1.48%	SMA200 ⓘ	2.48%	ATR ⓘ	0.39

ETF 簡介

Amplify Weight Loss Drug & Treatment ETFTHNR | NYSE | 一般 ETF 查看深度分析

Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.

THNR ETF 一覽

0.59% 越低越好

$6M 管理資產

22檔

1.59%

掛牌日 2024年

管理方式追蹤指數

發行公司 Amplify

主要持有標的持有 22 檔

前 3 大持股占 基金的 100%

集中在少數幾檔。它們波動時，ETF 也會跟著波動。